Tonix Pharmaceuticals Holding 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Tonix Pharmaceuticals Holding 's ROA in the second quarter of 2026?
Tonix Pharmaceuticals Holding Corp recorded a cumulative net loss of $-160 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -61.32%.

However, within the Healthcare sector 621 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4035, from total ROA ranking in the first quarter of 2026 at 4637.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	35.62 %	33.72 %	63.2 %	165.76 %	166.49 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-160	-147	-124	-99	-81
Return On Assets (TTM)	-61.32 %	-60.47 %	-54.52 %	-49.45 %	-50.49 %
TNXP's Total Ranking	# 4035	# 4637	# 4018	# 4091	# 4526
Total Assets (TTM) in million	254	258	277	252	187
Seq. Total Assets Change	-1.48 %	-6.95 %	9.8 %	34.74 %	-2.86 %
Seq. Net Income Change	-	-	-	-	-

TNXP's 5 Years Annual ROA >> Back to TNXP Management Effectiveness >> Compare TNXP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 279
Sector	# 622
Overall	# 4007

Return On Assets Statistics
High	Average	Low
-40.87 %	-135.07 %	-1050.68 %
(Jun 30 2022)		(Jun 30 2013)

News about Tonix Pharmaceuticals Holding Corp Return on Assets ROA

Tonix Pharmaceuticals' Tonmya Receives FDA Fast Track Designation for Fibromyalgia Treatment

Tonix Pharmaceuticals Tonmya Granted Fast Track Designation by FDA for Fibromyalgia Treatment
Fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and sleep disturbances, affects approximately 10 million Americans, primarily women. Currently, treatment options for fibromyalgia are limited, and many patients experience unsatisfactory symptom relief. However, there is renewed hope on the horizon as Tonix Pharmaceuticals recently received Fast Track designation from the U.S. Food and Drug Administration (FDA) for their drug Tonmya, aimed at addressing this unmet medical need.
Fast Track is a program initiated by the FDA to accelerate the development and review process of innovative drugs, particularly those targeting serious conditions or filling an unmet medical need. It is designed to expedite the approval timeline, ultimately allowing patients quicker access to potentially life-changing treatments.

Tonix Pharmaceuticals Receives FDA Blessing for Innovative PWS Treatment, Battling Financial Headwinds in the Race for a Breakthrough

Tonix Pharmaceuticals Holding Corp has recently achieved a significant milestone in its mission to develop innovative therapies for pediatric diseases. The company announced that it has been granted the highly coveted Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for its novel treatment, TNX-2900, aimed at addressing Prader-Willi Syndrome (PWS). This syndrome, characterized by an insatiable appetite and uncontrollable eating, affects thousands of children worldwide.
TNX-2900 offers a glimmer of hope for PWS patients and their families. Developed as a proprietary magnesium-potentiated formulation of intranasal oxytocin, this treatment harnesses the power of a naturally occurring hormone that has been proven to reduce appetite and curb overeating. By targeting the underlying cause of PWS, TNX-2900 has the potential to significantly improve the quality of life for these young patients.

Financial Statements
Tonix Pharmaceuticals Holding 's Assets	$ 254 million	TNXP's Balance sheet
Tonix Pharmaceuticals Holding 's Income	$ -41 million	Quarterly TNXP's Income Statement
TNXP's Income by Division		See TNXP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	70.7 %	5.13 %	-31.56 %	-5.96 %	147.6 %
Total Assets in million	277	162	154	226	240
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-124	-130	-117	-110	-92
Annual Return On Assets	-44.75 %	-80.08 %	-75.53 %	-48.84 %	-38.46 %

TNXP's 5 Years Annual ROA >> Back to TNXP Management Effectiveness >> Compare TNXP ROA to its Competitors

More Return On Assets Ratios
TNXP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TNXP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TNXP's Competitors
Subscribers only: Roa for Tonix Pharmaceuticals Holding 's Suppliers
Subscribers only: Return On Assets for TNXP's Customers

You may also want to know
TNXP's Roi	TNXP's Inventory Turnover Ratio	TNXP's Growth Rates	TNXP's Dividend Comparisons
	TNXP's Profitability Ratios	TNXP's Asset Turnover Ratio	TNXP's Dividend Growth
TNXP's Roe	TNXP's Valuation Ratios	TNXP's Financial Strength Ratios	TNXP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T22:38:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.